Damora Therapeutics Extends Cash Runway to 2029 with Strong Q1 Liquidity and Pipeline Progress
DMRA has more than doubled off its 52-week low of $2.45.
Summary
Damora Therapeutics reported a strong liquidity position in Q1 2026, extending its cash runway into 2029 following successful capital raises, despite increased R&D expenses for its advancing mutCALR pipeline.
Key Events · Earnings and Guidance · DMRA
-
Extended Cash Runway to 2029
Management projects existing cash and cash equivalents of $532.9 million as of March 31, 2026, will fund operations into 2029, significantly de-risking near-term liquidity concerns for the preclinical biotech.
-
Strong Liquidity Position
Cash and cash equivalents increased to $532.9 million as of March 31, 2026, up from $257.6 million at December 31, 2025, primarily driven by recent financing activities.
-
Substantial Capital Raises
The company completed a $295.5 million public offering in February 2026 at $19.00 per share and subsequently sold an additional 1,240,040 shares for $29.4 million in May 2026 via its ATM program at $24.16 per share.
-
Increased R&D Investment for Pipeline
Research and development expenses surged to $23.8 million for Q1 2026 from $0.7 million in Q1 2025, reflecting the strategic focus on advancing the mutCALR pipeline, including a $5.0 million expense for the Paramora Warrant Obligation.
Analysis · DMRA · Life Sciences
This quarterly report highlights Damora Therapeutics' significantly improved liquidity, with cash and equivalents more than doubling to $532.9 million by March 31, 2026, primarily due to recent capital raises. Management now projects this cash will fund operations into 2029, a critical de-risking factor for a preclinical biotech. While net losses and R&D expenses increased substantially, this reflects the company's strategic pivot and investment in its mutCALR pipeline, with regulatory submissions for lead candidates planned for mid-2026. The subsequent ATM sales in May 2026 at a price above the recent public offering further demonstrate market confidence in the company's funding strategy and pipeline.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DMRA was trading at $23.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $2.45 to $38.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.